Literature DB >> 20549479

[Vitiligo. What is new?].

K U Schallreuter1, M M A E L Salem.   

Abstract

Vitiligo occurs in Northern Europe in one of 200 people. The disease can cause significant psychological stress for the affected individual. These patients generate and accumulate massive amounts of H(2)O(2)- and peroxynitrite in the epidermal compartment. Consequently many proteins are oxidized or nitrated, leading in turn to partial or complete loss of functionality. Moreover, presence of DNA damage in the skin as well as in plasma has been shown, while apoptosis is not enhanced. Induction of DNA repair is associated with up-regulated functioning p53 protein. Considering possible genetic predisposition and /or spontaneous mutations, autoimmune reactions in the disease are put forward in the context of oxidative stress. In addition a review of recent and novel treatment modalities including the role of oxidative stress reduction and combined climatotherapy at the Dead Sea in a group are discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20549479     DOI: 10.1007/s00105-009-1916-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  36 in total

1.  Novel vitiligo susceptibility loci on chromosomes 7 (AIS2) and 8 (AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis.

Authors:  Richard A Spritz; Katherine Gowan; Dorothy C Bennett; Pamela R Fain
Journal:  Am J Hum Genet       Date:  2004-01       Impact factor: 11.025

Review 2.  A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?

Authors:  Yvon Gauthier; Muriel Cario Andre; Alain Taïeb
Journal:  Pigment Cell Res       Date:  2003-08

3.  The prevalence of pili multigemini.

Authors:  L Lester; C Venditti
Journal:  Br J Dermatol       Date:  2007-04-17       Impact factor: 9.302

Review 4.  Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo.

Authors:  E Helen Kemp; Nikos G Gavalas; David J Gawkrodger; Anthony P Weetman
Journal:  Autoimmun Rev       Date:  2006-10-02       Impact factor: 9.754

5.  Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature.

Authors:  M D Njoo; P I Spuls; J D Bos; W Westerhof; P M Bossuyt
Journal:  Arch Dermatol       Date:  1998-12

6.  Genetic association of the catalase gene (CAT) with vitiligo susceptibility.

Authors:  Courtney B Casp; Jin-Xiong She; Wayne T McCormack
Journal:  Pigment Cell Res       Date:  2002-02

7.  Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage.

Authors:  Mohamed M A E L Salem; Mohammad Shalbaf; Nicholas C J Gibbons; Bhaven Chavan; J M Thornton; Karin U Schallreuter
Journal:  FASEB J       Date:  2009-07-29       Impact factor: 5.191

8.  Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism.

Authors:  B A Salzer; K U Schallreuter
Journal:  Dermatology       Date:  1995       Impact factor: 5.366

9.  Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo.

Authors:  D A Buckley; S Rogers
Journal:  Clin Exp Dermatol       Date:  1996-01       Impact factor: 3.470

10.  Repigmentation in vitiligo vulgaris by autologous minigrafting: results in nineteen patients.

Authors:  B R Boersma; W Westerhof; J D Bos
Journal:  J Am Acad Dermatol       Date:  1995-12       Impact factor: 11.527

View more
  3 in total

1.  [Treatment of vitiligo].

Authors:  M Meurer; M Schild
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

2.  [Vitiligo: Clinical presentation and pathogenesis].

Authors:  M Schild; M Meurer
Journal:  Hautarzt       Date:  2016-02       Impact factor: 0.751

Review 3.  [Induction of occupational leucoderma and vitiligo. Can butylated hydroxytoluene induce vitiligo similarly to p-tert-butylphenol?].

Authors:  H C Broding; C Monsé; T Brüning; M Fartasch
Journal:  Hautarzt       Date:  2011-03       Impact factor: 0.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.